OncologyPRO: The home of ESMO’s educational and scientific resources

From ESMO Congress 2023:
The use of docetaxel alongside FOLFOX chemotherapy significantly improves outcomes for patients with treatment-naïve, HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinoma 

From ESMO Congress 2023:
Cabozantinib may offer a novel treatment option for patients with extra-pancreatic and pancreatic neuroendocrine tumours

From ESMO Congress 2023:
Combining prostate-specific membrane antigen-targeted radiotherapy and enzalutamide improves progression-free survival versus enzalutamide alone for high-risk metastatic castration-resistant prostate cancer

From ESMO Congress 2023:
Patients with progressive non-muscle-invasive bladder cancer and select FGFR mutations have better recurrence-free survival with oral erdafitinib than an investigator’s choice of intravesical chemotherapy

From ESMO Congress 2023:
The benefits of first-line afatinib for nonsquamous non-small-cell lung cancer extend to patients with uncommon sensitizing EGFR mutations

From the 2023 World Conference on Lung Cancer:
Latest findings from the AEGEAN trial indicate NSCLC surgical outcomes are not affected by perioperative durvalumab but that patients with an EGFR mutation do not benefit

From the 2023 World Conference on Lung Cancer:
Patients with ROS1 fusion-positive non-small-cell lung cancer show ongoing responses to repotrectinib when given as first- or second-line ROS1 tyrosine kinase inhibitor therapy 

From the 2023 World Conference on Lung Cancer:
The addition of platinum-based chemotherapy to first-line osimertinib improves progression-free survival for patients with advanced, EGFR-mutated non-small-cell lung cancer